Frontiers in Pharmacology (Feb 2020)

Compound C Reducing Interferon Expression by Inhibiting cGAMP Accumulation

  • Junzhong Lai,
  • Junzhong Lai,
  • Xuan Luo,
  • Xuan Luo,
  • Shuoran Tian,
  • Shuoran Tian,
  • Xing Zhang,
  • Xing Zhang,
  • Shanlu Huang,
  • Shanlu Huang,
  • Hanze Wang,
  • Hanze Wang,
  • Qiumei Li,
  • Qiumei Li,
  • Shaoli Cai,
  • Shaoli Cai,
  • Qi Chen,
  • Qi Chen

DOI
https://doi.org/10.3389/fphar.2020.00088
Journal volume & issue
Vol. 11

Abstract

Read online

Cyclic GMP-AMP (cGAMP) synthase (cGAS) is a major DNA sensor responsible for cytosolic DNA-mediated innate immune response. Inhibition of cGAS may be an effective strategy for treating autoimmune diseases such as Aicardi-Goutieres syndrome and systemic lupus erythematosus. Compound C (also known as Dorsomorphin) has been annotated as a potent and reversible inhibitor for AMPKs as well as ALK protein kinases. Here, we report a new function of Compound C which can suppress dsDNA-dependent type I interferon induction. These effects were not dependent on the activities of AMPK proteins. In vitro assays and liquid chromatograph-mass spectrometry data show that Compound C has the capability of reducing cGAMP accumulation, suggesting that Compound C may function as a modulator involved in the cGAS-STING-mediated DNA sensing pathway. Furthermore, Compound C is able to rescue the autoimmune phenotypes in a mouse model carrying the Trex1 gene deficiency. These data demonstrate a new and inverse correlation between Compound C and type I interferon production in response to dsDNA signaling.

Keywords